Merck licenses SciBrunch KRAS G12D inhibitor in deal worth up to $2.13bn
Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.
SciBrunch will receive $400 million upfront, with additional development, commercial and other milestone payments potentially taking the total transaction value to $2.13 billion.
The agreement gives Merck a preclinical oral KRAS G12D (ON) inhibitor targeting one of the most important oncogenic mutations across multiple tumour types.
Field | Content |
Article Type | Deals |
Companies | Merck; SciBrunch Therapeutics |
Deal Type | Exclusive global licensing agreement |
Asset | SPR2015 |
Therapy Areas | Oncology |
Technology/Modality | Oral KRAS G12D (ON) inhibitor |
Development Stage | Preclinical |
Upfront Payment | $400 million |
Potential Deal Value | Up to $2.13 billion |
Geography | Worldwide |
What Happened | Merck secured exclusive worldwide rights to SciBrunch Therapeutics' investigational oral KRAS G12D (ON) inhibitor SPR2015. |
Why It Matters | The transaction adds a targeted oncology programme directed at KRAS G12D, a major oncogenic driver across several difficult-to-treat cancers. |
Supporting Context | SPR2015 is a preclinical small-molecule programme designed to inhibit the active ON state of KRAS G12D. |
Strategic Rationale | Merck gains a potentially differentiated KRAS-targeted asset for its oncology pipeline while SciBrunch receives substantial upfront funding and downstream milestone opportunities. |
Potential Impact | Successful development could expand targeted treatment options for patients with KRAS G12D-mutated cancers. |
Key Takeaway | Merck is paying $400 million upfront for SPR2015 in a licensing transaction worth up to $2.13 billion. |
What to Watch | IND-enabling development, entry into clinical trials and initial evidence of activity across KRAS G12D-mutated tumours. |
Primary Source | Merck |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments